Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec;4(23):472.
doi: 10.21037/atm.2016.11.05.

Uncovering first molecular mechanisms of secondary resistance against PD-1 blockade

Selma Ugurel  1
Affiliations
Comment

Uncovering first molecular mechanisms of secondary resistance against PD-1 blockade

Selma Ugurel. Ann Transl Med. 2016 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest to declare.

Comment on

  • Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
    Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Zaretsky JM, et al. N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13. N Engl J Med. 2016. PMID: 27433843 Free PMC article.

References

    1. Callahan MK, Flaherty CR, Postow MA. Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer Treat Res 2016;167:231-50. 10.1007/978-3-319-22539-5_9 - DOI - PubMed
    1. Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer 2016;53:125-34. 10.1016/j.ejca.2015.09.013 - DOI - PubMed
    1. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:1270-1. 10.1056/NEJMoa1504030 - DOI - PubMed
    1. McDermott D, Lebbé C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40:1056-64. 10.1016/j.ctrv.2014.06.012 - DOI - PubMed
    1. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9. 10.1158/1078-0432.CCR-13-0143 - DOI - PubMed

LinkOut - more resources